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Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is associated with enhanced leukocyte
infiltration to the gut, which is directly linked to the clinical aspects of these disorders. Thus, leukocyte traﬃcking is a major target
for IBD therapy. Past and emerging techniques to study leukocyte traﬃcking both in vitro and in vivo have expanded our knowledge
of the leukocyte migration process and the role of inhibitors. Various strategies have been employed to target chemokine- and
integrin-ligand interactions within the multistep adhesion cascade and the S1P/S1PR1 axis in leukocyte migration. Though there
is an abundance of preclinical data demonstrating eﬃcacy of leukocyte traﬃcking inhibitors, many have yet to be confirmed in
clinical studies. Vigilance for toxicity and further research is required into this complex and emerging area of IBD therapy.
1. Introduction
Leukocyte migration is fundamental to immunologic mobi-
lization in response to insult and injury. A coordinated series
of molecular events underpins the traﬃcking of lymphocytes
and granulocytes into stressed tissue with participation of
adhesion molecules, chemokines, and their receptors.
The inflammatory bowel diseases (IBDs), Crohn’s disease
(CD) and ulcerative colitis (UC), are distinct syndromes, but
both are associated with enhanced leukocyte traﬃcking to
the inflamed gut. Thus, targeting the multistep leukocyte
adhesion cascade has been employed as a therapeutic
strategy. Here, we focus on the contribution of leukocyte
traﬃcking to the pathogenesis of IBD. An overview of
strategies employed to target leukocyte recruitment and of
emerging models used to test these targets is presented.
2. IBD
Crohn’s disease and ulcerative colitis are recurring, relapsing,
and remitting disorders characterized by chronic inflam-
mation of the intestinal mucosa. Though they share some
common clinical symptoms such as diarrhea and abdominal
pain, CD and UC possess very distinct features. Crohn’s dis-
ease manifests as a transmural inflammation that can poten-
tially develop anywhere along the gastrointestinal tract but
primarily occurs in the terminal ileum and proximal colon.
Ulcerations, granulomas, and bowel fistulas are characteristic
histopathological features. In contrast, ulcerative colitis
seldom ulcerates and is a relatively superficial inflammation
of the mucosa that is diﬀuse, continuous, and restricted to
the colon, usually extending proximally from the rectum. It
is characterized by significant goblet cell depletion and crypt
abscesses, but granuloma development is not a feature. In
both CD and UC, leukocyte infiltration into the inflamed
intestine is fundamental to disease development and perpet-
uation. The infiltrated eﬀector cells resist apoptosis and per-
sistently release harmful inflammatory cytokines causing tis-
sue damage. In CD, the characteristic granulomas form upon
dense accumulation of activated T cells and macrophages.
Ulcerative colitis is characterized by excessive mucosal
infiltration of T cells and neutrophils, the latter forming
the characteristic crypt abscesses [1]. The pivotal role of T
cells, neutrophils, and their proinflammatory cytokines in
the pathogenesis of IBD has been reviewed elsewhere [2, 3].
Genetic and environmental risk factors have been impli-
cated in IBD (for reviews see Xavier and Podolsky [1], Melgar
and Shanahan [4], and Cho and Brant [5]). Despite extensive
research, current therapeutic options in IBD remain limited,
often varying in their maintenance, toxicity, and tolerability
[6–8]. Novel therapeutic strategies for IBD are needed.
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3. Leukocyte Trafficking
3.1. In Vitro and In Vivo Models of Leukocyte Traﬃcking
3.1.1. Traditional Methods. The concept of lymphocyte recir-
culation and homing was first demonstrated by Gowans
and Knight in 1964, when they followed the migration of
radiolabeled lymphocytes in rats using autoradiography and
scintography [9]. They and others found that while naı¨ve
lymphocytes migrated to all secondary lymphoid tissues,
activated lymphocytes preferentially migrated back to the
tissue in which they had been exposed to the antigen. In order
to devise rational therapeutic strategies that target leukocyte
migration, it is important to elucidate leukocyte traﬃcking
patterns in vivo. Techniques employed to study leukocyte
traﬃcking frequently involve ex vivo labeling of donor cells
and adoptive transfer into recipient animals. Subsequently,
the distribution of the labeled cell population in recipient
tissues is assessed using a variety of imaging methods, such
as histological analysis of fixed tissues. This technique has
provided us with valuable mechanistic knowledge, but it
does not permit direct examination of dynamic processes at
single-cell level or provide temporal or spatial information
within the physiological environment of lymphoid tissues.
Furthermore, labeling of cells ex vivo has been associated
with variable labeling eﬃciency, alteration of cellular func-
tions, and label elution postadoptive transfer. Radiolabeling
techniques, such as white cell scintigraphy, have been used
to successfully study neutrophil migration in clinical IBD
studies [10]. However, such methods are hampered by
radioactive decay, poor resolution, and cellular toxicity [11].
Myeloperoxidase (MPO) assays are commonly used to study
neutrophils and quantitate neutrophil influx, but they do
not distinguish between neutrophils and macrophages and
can be problematic to carry out. Similarly, while in vitro
chemotaxis assays are regularly employed to analyze the
eﬀects of potential inhibitors on cell migration, there is no
guarantee that the cells will respond in the same way to the
test compound in vivo. Multiphoton intravital microscopy
has been widely used to image the dynamic movement
of lymphocytes by tracking fluorescently labeled cells in
exposed or explanted lymph nodes (LNs) of living animals.
This technique has provided valuable insights into the
dynamics of T- and B-cell homing to LNs [12, 13] and allows
single-cell tracking, in conjunction with high-resolution
images. Nonetheless, intravital microscopy is an invasive
technique, and the surgery required may interfere with the
flow of blood and lymph creating experimental artifacts.
3.1.2. Molecular Imaging Techniques. Molecular imaging is
defined as “the visualization, characterization and measure-
ment of biological processes at the molecular and cellular
levels in humans and other living systems” [14]. Over the
past decade, a number of such techniques have been adapted
to small animal imaging, oﬀering dynamic imaging methods
to localize leukocytes in vivo. Positron emission tomog-
raphy (PET) [15] and single-photon emission-computed
tomography (SPECT) [16, 17] use scintillation cameras
and other devices to detect radioactive emission from
radiolabeled cells within the body. Though these nuclear
imaging methods have excellent tissue penetration and cell
quantitation capability, they too are subject to the drawbacks
associated with radiotracers and exogenous labeling of cells.
Magnetic resonance imaging (MRI), which relies on the
nuclear resonance of protons in tissues upon scanning with
radio frequency radiation, has shown great promise to track
the recruitment of, for example, antigen-specific CD8+ T
cells to target tumors in vivo [18]. However, the time required
for imaging using this technique makes it unsuitable for
tracking fast-moving cells [19]. The substantial expense
of MRI and its relatively poor sensitivity and quantitative
capability have also hindered its use as a basic research tool.
Optical fluorescence imaging has been frequently used to
track T cells and has provided us with invaluable data on
their migration patterns. The pitfalls with using fluorescent
labels, such as CFSE and GFP, include signal loss due to
label dilution upon cell division and limited sensitivity and
specificity due to endogenous tissue autofluorescence and
light scattering and absorption [20].
3.1.3. Bioluminescence Imaging. To illuminate cell traﬃcking
in vivo and to test specific inhibitors of this migration, we
used bioluminescence imaging (BLI) technology [21–23].
This form of optical imaging has several advantages over
other techniques for tracking cell migration. It eliminates the
necessity to prelabel cells, avoiding problems with exogenous
cell labeling. It allows direct in vivo and ex vivo visualization,
with no further processing of tissues required, and is, there-
fore, a less complicated and less labor intensive technique
than most other in vitro/ex vivo methods. Unlike other
molecular imaging methods, BLI combines high sensitivity
with relatively low cost while providing quantitative, spatial,
and temporal data. However, this technology has limitations.
Since light transmission through animal tissues is wavelength
dependent, loss of photon signal can occur with tissue
depth and light sources closer to the surface of the animal
can appear brighter. In addition, validation of potential
therapeutics using BLI should be carried out in conjunction
with in vitro mechanistic assays and in vivo eﬃcacy studies.
BLI has successfully monitored traﬃcking of bone marrow
mononuclear cells in ischemic myocardium [24] and CD4+
T cells in an experimental model of multiple sclerosis (MS)
[25]. These and other studies have shown robust and reli-
able correlation between cell numbers and bioluminescence
signals. We employed BLI to track both neutrophils and
lymphocytes in murine models of experimental colitis and to
test potential inhibitors of their migration Figure 2 [21, 22].
3.2. The Leukocyte Traﬃcking Cascade
3.2.1. Selectins, Integrins, and Their Ligands. Circulating
leukocytes are subjected to extreme conditions with the flow
of blood exerting a shearing stress on the cells dislodging
any that touch the vascular wall. To leave the circula-
tion and home to specific tissues, leukocytes must engage
several adhesion pathways involving intimate interaction
with endothelial cells [26]. Whether during physiological
recirculation or inflammatory conditions, the mechanisms
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involved in leukocyte traﬃcking are eﬀectively the same.
The leukocyte traﬃcking cascade is depicted in Figure 1.
Leukocyte recruitment begins with tethering and rolling
of the cells along the microvascular endothelium via three
selectins: L-selectin, expressed by leukocytes, and E-selectin
and P-selectin, expressed by inflamed endothelial cells on
the blood vessel wall [27]. The ligand P-selectin glycoprotein
ligand-1 (PSGL-1) binds all three selectins and plays an
important role in leukocyte recruitment under inflammatory
conditions [28]. L-selectin is constitutively present on T cells
and interacts with its counter receptors, peripheral lymph
node addressin (PNAd) and mucosal addressin cell adhesion
molecule (MAdCAM)-1, acting as a mechanical anchor or
tether to the high endothelial venules (HEVs). This allows
the lymphocytes to roll along the vascular lining at a much
slower pace than erythrocytes. Selectins engage rapidly and
form strong bonds to secure contact. These bonds allow
chemokines and their ligands to transmit activating signals
for the next step in the migration cascade. Targeting selectins
and their ligands as a treatment strategy for inflammatory
disorders has been reviewed elsewhere [29].
Selectin bonds are unable to arrest cells at the vessel wall.
Firm leukocyte adhesion is achieved through bonds formed
downstream by the secondary adhesion molecules, integrins.
Integrins are diversely expressed on diﬀerent leukocyte
subpopulations and are composed of noncovalently linked
α and β chains. The α4 integrins, α4β1 and α4β7, play a
regulatory role in lymphocyte homing and recruitment to
inflammatory tissues, particularly to the inflamed intestine.
Two decades ago, it was revealed that memory T cells
from the gut preferentially homed to the gut [30]. This
phenomenon is linked to the expression of unique adhesion
molecules within the mucosa [31, 32]. Both α4β1 and
α4β7 are expressed by lymphocytes that reside in the gut
and gut-associated lymphoid tissues (GALTs), and their
respective ligands vascular cell adhesion molecule (VCAM)-
1 and MAdCAM-1 are expressed within the HEV’s in Peyer’s
patches (PPs) and the flat-welled venules of the lamina
propria [33]. While the α4β7-MAdCAM-1 interaction is
restricted to leukocyte traﬃcking to the gut and GALT, the
α4β1-VCAM-1 pathway can also mediate leukocyte homing
to the central nervous system, specifically to the inflamed
brain [34]. Interestingly, mice deficient in the β7 integrin
gene are unable to form proper PPs and possess decreased
numbers of lamina propria CD4+ T cells and B cells [35].
The β2 integrins are also prominent participants in leukocyte
traﬃcking, mediating firm adhesion, particularly in the case
of neutrophils [36]. The β2 integrin lymphocyte function-
associated antigen (LFA)-1 is predominantly expressed by
lymphocytes and neutrophils and binds to its endothelial
cell ligands intercellular adhesion molecule (ICAM)-1 and
ICAM-2. In addition to leukocyte arrest, integrins can par-
ticipate in leukocyte rolling. Under inflammatory conditions,
lymphocytes can skip the selectin-mediated phase and bind
directly to endothelial cells via α4β7 [37].
Abundant evidence reveals that IBD is associated with
enhanced leukocyte traﬃcking to the gut mucosa and
altered expression of adhesion molecules [38]. Cytokines
such as interleukin (IL)-1β, IL-6, and TNF-α, produced
upon stimulation of innate immune cells at inflammatory
sites [39], upregulate adhesion molecules and chemokines,
enhance leukocyte recruitment, and amplify the inflamma-
tory cascade. Expression of MAdCAM-1 is upregulated in
animal models of colitis [40, 41] and in active IBD [42–
44]. ICAM-1 and LFA-1 have also been implicated in a
number of experimental animal models of IBD [45, 46]. The
importance of adhesion molecules in IBD is evident from
preclinical colitis studies, where their blockade ameliorated
disease severity [47]. Table 1 summarizes preclinical and
clinical data reported so far. Similar results have been
reported in animal models of autoimmune disease including
MS and rheumatoid arthritis [48].
3.2.2. Chemokines and Their Receptors. Chemokines mediate
cell migration under normal physiological conditions and
leukocyte recruitment to tissues during innate and adaptive
immune responses. These small heparin-binding proteins
come from a diverse family that is classified into four major
subfamilies, CC, CXC, C, and CX3C, based on structural and
functional diﬀerences. The two most important subgroups
in terms of leukocyte traﬃcking to inflamed tissues are the
CC chemokines for dendritic cell (DC) and lymphocyte
recruitment and the CXC chemokines for recruitment of
neutrophils and monocytes. Chemokines exert their bio-
logical eﬀects on target cells by binding to specific G-
protein-coupled transmembrane receptors (GPCRs) on the
cell surface and activating an intracellular signaling cascade.
Consequently, an activating signal is sent to the integrin
switching it into a high-aﬃnity/high-avidity state so that the
rolling leukocyte can arrest itself and firmly adhere to the
HEVs, a step which is essential for leukocyte extravasation
into the target tissue [74]. For example, binding of CCR7
on naı¨ve T cells to its chemokine ligand CCL21 on HEVs in
turn activates binding of α4β7 and LFA-1 to their endothelial
ligands MAdCAM-1 and ICAM-1, respectively [38]. In addi-
tion, the combined expression of chemokine receptors and
adhesion molecules by naı¨ve and memory T lymphocytes
govern their selective homing patterns. For instance, while L-
selectin and CCR7 regulate naı¨ve T-cell migration to periph-
eral LNs, expression of α4β7 in conjunction with CCR9
allows T-cell migration to the skin and gut. The encounter
between CCR7 and its ligands CCL19 and CCL21 bridges
the gap between innate and adaptive immune responses. Up-
regulation of CCR7 on antigen-laden DCs facilitates their
migration into LNs for T-cell priming. In addition, enhanced
expression and binding of CCR7 on naı¨ve T cells to CCL19
on DCs and CCL21 on HEVs mediate transmigration from
peripheral tissues into LNs. In contrast, downregulation
of CCR7 allows activated T cells to exit the LN area and
migrate to target tissues to carry out eﬀector functions
[75, 76]. Furthermore, elevated expression of CXCR5, the
ligand of CXCL13, on certain CD4+ T cells directs their
migration to the follicle to provide B-cell help [77]. Upreg-
ulated mucosal expression of numerous chemokines and
their counter receptors including CXCL8 (IL-8)/CXCR2,
CXCL9,10,11/CXCR3, CCL25/CCR9, CCL19,21/CCR7, and
CCL20/CCR6 is evident in active IBD and in models of
colitis [78–80]. Thus, chemokines orchestrate the activation,
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Figure 1: Schematic view of the leukocyte traﬃcking adhesion cascade in IBD. Leukocytes tether and roll along the vascular endothelium via
selectin-mediated adhesion. They are then activated by chemokines into a high avidity, high aﬃnity state so that integrin-mediated strong
adhesion and arrest can take place. This prepares the leukocyte for transmigration through the blood vessel wall into the inflamed colon.
Chemokine activation can be inhibited by various chemokine/chemokine receptor inhibitors such as the CCR9 small molecule antagonist
Traficet-EN, a monoclonal antibody to CXCR3 or a CXCR2 antagonist (shown in blue). Additionally, antagonists of integrin firm adhesion
include the anti- α4 integrin monoclonal antibody Natalizumab, the selective α4β7 small molecule antagonist MLN-02 and the antisense
intercellular adhesion molecule-1 (ICAM-1) oligonucleotide Alicaforsen (shown in blue). KO, knock out; LFA-1, Lymphocyte function-
associated antigen 1; MadCAM-1, mucosal addressin-cell adhesion molecule 1; PNAd, Peripheral lymph node addressin; RBC, red blood
cell; V-CAM-1, vascular-cell adhesion molecule 1.
recruitment, and retention of leukocytes, and, the more
insight we gain into their vital role, the more attractive they
become as potential therapeutic targets.
3.2.3. The Role of DCs in Lymphocyte Homing to the Gut.
The specific homing receptors expressed by activated T cells
are determined by DCs. Several murine studies show that
DCs from mesenteric lymph nodes (MLNs) or PPs imprint
gut tropism on antigen-experienced T cells, by inducing
expression of the gut homing receptors α4β7 and CCR9 [81–
83]. In the “steady state” mouse intestine, the ability to
confer gut homing specificity is restricted to the CD103+
intestinal DC subset [84–86]. The vitamin A metabolite
retinoic acid (RA) plays a central role in the process of
DC imprinting within lymphoid tissues. For instance, mice
deficient in vitamin A have decreased numbers of T cells in
the intestine [37, 87, 88]. However, the dependency of DC-
T-cell imprinting on retinoic acid receptor (RAR) signaling
is complex and not yet fully characterized [89]. Also, the key
factors that induce DC imprinting activity have yet to be
identified; for example, germ-free studies have indicated that
gut bacteria are not required for intestinal DC imprinting of
α4β7 expression [90]. The specific role played by intestinal
DC imprinting in IBD remains elusive, but presumably
it influences the increased numbers of α4β+7 and CCR9
+
lymphocytes evident in the inflamed intestine [91]. Since
the CD103+ intestinal DC subset favors the generation of
Foxp3+ T-regulatory cells (Tregs) over Th17 cells, via a TGF-
β- and RA-dependent mechanism [92], targeting leukocyte
traﬃcking at the DC imprinting level may represent a
potential therapeutic strategy for IBD. Notably, a diet low in
vitamin A protects against colitis in mice, and this protection
is associated with increased levels of Tregs in the gut mucosa.
In this case, the reduced availability of RAR ligands aﬀects
lymphocyte homing to the gut by decreasing entry of α4β7
and CCR9+ T cells in favor of Tregs [93].
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Table 1: Targeting leukocyte traﬃcking in inflammatory bowel disease.
Target Drug type Preclinical eﬃcacy Therapeutic Clinical eﬃcacy
Adhesion molecules
α4 Integrins/ligands
Antisense MAdCAM-
1 oligonucleotide
TNBS colitis [49, 50]
Natalizumab
(humanized IgG4 mAb
anti-α4 integrin)
CD (Phase IV) [51, 52]
Prevented relapse,
induced remission
Anti-VCAM-1 mAb UC [53] Pilot study
Anti-MAdCAM-1
mAb
DSS colitis [54, 55]
AJM300 (orally
available anti-α4
integrin mAB)
CD (Phase II) [56]
Reduced disease
activity, good
safety profile
Small molecule α4
integrin antagonist
DSS colitis [22]
Anti-β7 and
anti-MAdCAM-1
mAb
T-cell transfer colitis
[57]
Vedolizumab/MLN-02
(humanized IgG4 mAb
α4β7 integrin)
CD [58],
UC Phase II [59, 60]
Induced clinical
response and
remission, good
safety profile
Anti-MAdCAM-1
mAb
SAMP1/Yit mice [61]
Anti-α4β7 mAb
Cotton top tamarin
model [62]
ICAM-1/LFA-1
Anti-ICAM-1 mAb
Antisense ICAM-1
oligonucleotide
DSS colitis [63, 64]
Alicaforsen (ISIS2303)
(antisense ICAM-1
oligonucleotide)
UC (Phase II) [65, 66]
Reduced disease
activity, good
safety profile
Anti-ICAM-1 mAb SAMP1/Yit mice [67]
Chemokines
CCR9/CCL25
Anti-CCR9/CCL25
mAb Traficet-EN
(CCX282-B)
SAMP1/Yit mice [68]
TNF (DeltaARE)
mice [69]
Traficet-EN/CCX282-B
(small molecule CCR9
antagonist)
CD (Phase III) [70]
Induced clinical
remission, good
safety profile
CXCR3/CXCL10 Anti-CXCL10 mAb
IL-10 KO [71, 72]
DSS colitis [73]
MDX-1100 (humanized
anti-CXCL10 mAb)
UC (Phase II)
NCT00295282
NCT00656890
CD: Crohn’s disease; DSS: dextran sodium sulphate; ICAM-1: intercellular adhesion molecule 1; MadCAM: mucosal addressin-cell adhesion molecule 1;
senescence accelerated mice (SAMP1/Yit); TNBS: trinitrobenzene sulfonic acid; UC: ulcerative colitis; V-CAM-1: vascular-cell adhesion molecule 1.
3.2.4. S1P and Control of Leukocyte Egress from Tissues. While
chemokines control naı¨ve T-cell migration to and within
LNs, the natural bioactive lipid sphingosine-1-phosphate
(S1P) regulates lymphocyte egress. S1P is formed upon
the phosphorylation of sphingosine by sphingosine kinase
and mediates a number of fundamental biological events
including endothelial barrier enhancement, lymphocyte dif-
ferentiation and immune cell traﬃcking [94]. Levels of S1P
in the blood and lymph are constitutively high while they are
low in tissues, increasing substantially upon inflammation.
Although synthesized in most cells, tissue levels of S1P are
tightly controlled due to intracellular degradation by S1P
lyase or phosphorylation by S1P phosphatases. Five S1P
receptors have been described so far, S1PR1–5, and are
expressed in a cell-type specific manner within diﬀerent
tissues [95]. S1PR1–3 are ubiquitously expressed in mam-
mals [96], while S1PR4 expression is restricted to lymphoid
tissues [97] and lung, and S1PR5 to brain, skin, and natural
killer (NK) cells [98]. The S1P/S1PR1 axis is essential for
lymphocyte egress from the thymus and spleen into the
blood and from the LNs into the lymph [99]. During
T-cell priming, elevated expression of CD69 on activated
lymphocytes promotes the temporary downregulation of
S1PR1 expression on the cell membrane, disabling ligation to
S1P and consequently trapping them within the LNs [100].
Concurrent binding of CCR7 to its ligand CCL21 mediates
competitive retention signals. Following clonal expansion,
CCR7 expression is lost and S1PR1 expression is upregulated
once again, allowing the eﬀector T cells to leave the lymphoid
tissues, reenter the systemic circulation, and rapidly migrate
to sites of inflammation [101]. The S1P/S1PR interaction
also regulates themovement of DCs [102], neutrophils [103],
and NK cells [104]. S1P signaling and functions in immunity
have been reviewed elsewhere [105].
The discovery that the S1P/S1PR1 axis is essential for
lymphocyte egress added a new potential target for blocking
leukocyte migration in inflammatory diseases. Disruption of
this S1P gradient has been reported in numerous inflamma-
tory and/or autoimmune disorders including asthma [106]
and rheumatoid arthritis [107]. The novel immunosuppres-
sant FTY720 (Fingolimod) [108] is structurally similar to
S1P and poses as an S1P analog. Like S1P, it is phosphorylated
in vivo and binds with high aﬃnity to 4 of the 5 S1P receptors
S1PR1, S1PR3, S1PR4, and S1PR5 [109]. FTY720 interferes
with S1P signaling and blocks the response of lymphocytes
to egress signals from the lymphoid organs, sequestering
them within the LNs and PPs. The result is a rapid and
dramatic peripheral blood lymphopenia with depletion of
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circulating T and B cells. In contrast, FTY720 increases the
number of DCs in the blood and simultaneously reduces
their numbers in secondary lymphoid organs. In addition,
it can modulate DC cytokine signaling potentially aﬀecting
T-cell responses [110]. The mechanism of action of FTY720
is complex, and it is currently unclear whether it acts as an
agonist or functional antagonist or both during regulation
of lymphocyte recirculation in vivo. Since FTY720 inhibits
cell migration to inflammatory sites, it has shown great
potential as a treatment for inflammatory disorders [108].
In clinical studies, FTY720 successfully prevented kidney
transplant rejection [111–114] and proved highly eﬀective
in treating MS. It was recently approved by the US Food
and Drug Administration (FDA) as a first-line treatment for
relapsing forms of MS. In terms of IBD, FTY720 ameliorated
experimental colitis arising as a result of chemical induction
[115–117], T-cell transfer [118], and IL-10 deficiency [119],
suggesting it may be a potential candidate for IBD treatment.
However, reports of side eﬀects such as bradycardia and
increased susceptibility to opportunistic infections [108]
dictate that the use of FTY720 therapeutically should be
approached with caution and that perhaps using more
selective drugs to target the S1P receptor pathway may be a
safer option and yield less side eﬀects. Indeed, the specific
agonist of S1PR1, SEW2871, has shown promise in preclin-
ical kidney transplantation studies [120] and exhibited anti-
inflammatory eﬀects in mice administered TNF-α [121]. In
addition, another selective S1PR1 agonist KRP-203 showed
therapeutic potential in IL-10-deficient mice [122].
4. Preclinical and Clinical Evidence of
Targeting Adhesion Molecules
Figure 1 and Table 1 summarize the data presented under
Sections 4 and 5.
4.1. Natalizumab. Promising preclinical data [22, 49, 50, 54,
55, 57, 61, 62] (also see Table 1) led to the use of humanized
α4 integrin antibodies in clinical trials. The most well-known
anti-α4 drug is Natalizumab (Tysabri), a humanized pan-
α4 monoclonal antibody. Natalizumab blocks the ability
of α4β1 and α4β7 to bind to their respective ligands on
the endothelium, preventing lymphocyte transendothelial
migration. This α4 antagonist was approved by the FDA in
2004 and is highly eﬀective in treating the symptoms of MS
[123, 124] and in preventing relapse and increasing remis-
sion rates in suﬀerers with moderate to severe CD [51, 52].
Natalizumab therapy has been associated with cases of pro-
gressive multifocal leukoencephalopathy (PML) in a small
number of patients, which is induced by the JC virus, an
opportunistic infection of the brain [125]. Though rare, PML
is a serious and often fatal disease. The approval and relative
success of Natalizumab have heightened interest and greatly
encouraged further research into targeting integrins and
their counter adhesion molecule ligands as a novel treatment
strategy for chronic inflammatory diseases, including IBD.
4.2. MLN-02. Vedolizumab (MLN-02) is a recombinant
humanized IgG1 monoclonal antibody selective for the
gut-specific integrin α4β7. By binding to α4β7, MLN-02
inhibits the adhesion and migration of leukocytes into the
gastrointestinal tract, preventing intestinal inflammation.
MLN-02 treatment ameliorated disease in the cotton top
tamarin model of colitis [126] and safely and eﬀectively
induced clinical response and remission in two double-
blinded placebo-controlled clinical trials of patients with
active CD and UC [58–60]. The selectivity of MLN-02 makes
it less likely to impair systemic immunity andmore attractive
as a therapeutic target for IBD.
4.3. Alicaforsen- (ISIS2302-) and LFA-1-Targeting Drugs.
Alicaforsen, a human ICAM-1 antisense oligonucleotide,
inhibits ICAM-1 production preventing T-cell adhesion,
extravasation, and subsequent migration to inflamed areas
[127]. Blocking ICAM-1 ameliorated colitis in a number
of preclinical models [63, 64, 67]. In clinical studies, this
approach has had variable success and in general has yielded
disappointing results in the treatment of CD [128–130].
However, there have been promising results with an enema
formulation of Alicaforsen in the treatment of UC [65]
and refractory pouchitis [131]. Efalizumab, a humanized
monoclonal IgG1 antibody treatment for plaque psoriasis, is
FDA approved and also acts by blocking the LFA-1/ICAM-
1 interaction. By doing this it inhibits T-cell migration to
the inflamed dermal and epidermal tissues. However, similar
to Natalizumab, serious adverse eﬀects, such as the Epstein-
Barr virus-associated B-cell lymphoma development, were
reported following treatment [132].
4.4. Small Molecule Antagonists. The immunogenicity of
antibody therapies has increased research into the use of
nonpeptide small molecule antagonists to block leukocyte
traﬃcking. Such therapeutics are less likely to elicit the
undesirable and serious immunogenic responses associated
with monoclonal antibody therapy, and, unlike antibodies,
they can be taken orally and are less expensive to produce.We
analyzed the leukocyte traﬃcking blockade eﬀect of a small
molecule α4 integrin antagonist in a preclinical model of
IBD.We confirmed the therapeutic eﬃcacy of the compound
in dextran sodium sulphate- (DSS-) induced acute colitis and
demonstrated its ability to inhibit leukocyte traﬃcking to the
inflamed gastrointestinal tract in vivo using bioluminescence
imaging, as shown in Figure 2 [22]. Previous studies using
small molecule integrin antagonists in other models of
inflammatory disease have also shown promising results
[133, 134].
5. Preclinical and Clinical Evidence of
Targeting Chemokines
5.1. CCR9. The chemokine CCR9 is exclusively expressed
by gut homing leukocytes and interaction with its counter
ligand CCL25 is essential for T-cell homing to the small
intestine [135]. The CCR9/CCL25 interaction specifically
contributes to the pathophysiology of small bowel CD [136].
Antibody blockade of this interaction reduced inflammation
in early stages of chronic ileitis in senescence accelerated
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Figure 2: Inhibition of leukocyte migration by an α4 integrin antagonist in experimental colitis. Leukocytes were isolated from mesenteric
lymph nodes (MLNs) of β-actin luciferase mice and injected into recipient mice with dextran sodium sulphate- (DSS-) induced colitis.
The recipient mice received vehicle or α4 antagonist, 1 hour pre cell transfer. Whole body and organs ex vivo (colon and small intestine)
were imaged using an IVIS 100 charge-coupled device imaging system 4 hours following transfer. The pseudocolored images represent light
intensity, where red is the strongest, and violet is the weakest signal. Inhibition is detected in the colon and in Peyer’s patches of the α4
antagonist-treated mice.
(SAMP1/Yit) mice [68]. Additionally, pre- or post admin-
istration of a small molecule CCR9 antagonist (CCX282-
B/Traficet-EN) reduced gut inflammation in TNFΔARE
mice, an experimental model of CD [69]. Interestingly,
Wermers et al. recently demonstrated that blockade of
CCR9 exacerbated chronic ileitis in these mice, by inhibiting
recruitment of Tregs to the small intestinal lamina propria
and MLNs [137]. The exact role of CCR9/CCL25 in large
intestinal inflammation remains unclear, and studies have
yielded conflicting results. Preliminary clinical data using
Traficet-EN demonstrated a beneficial therapeutic eﬀect in
both patients with ileal and colonic CD, by significantly
reducing proinflammatory cytokine levels and disease scores
and maintaining clinical remission [70]. This is surprising,
since there is little or no expression of CCL25 in the colon
[138, 139]. However, recent data showed that, although
colonic levels of CCL25 are low in healthy mice, they
are significantly upregulated upon DSS-induced colitis. In
addition, CCR9 knock-out (KO) mice with acute DSS colitis
exhibit enhanced severity of clinical symptoms and tissue
injury and display delayed recovery. Exacerbation of disease
was associated with an imbalance in DC subpopulations
and increased macrophage infiltration into the colon [138].
These data suggest that use of CCR9 blockade therapy in, for
example, strictly colonic UC, could have detrimental eﬀects.
5.2. CXCR3. CXCR3 is expressed by monocytes, T cells,
and NK cells and can mediate their recruitment to inflam-
matory sites by binding to its ligands CXCL9, CXCL10,
and CXCL11. CXCR3 engagement with these chemokines
mediates the rapid arrest of eﬀector T cells in vitro [140] and
selectively mobilizes high-CXCR3-expressing Th1 cells to
sites of mucosal inflammation [141]. Expression of CXCR3
and its chemokine ligands is elevated in both preclinical
and clinical models of IBD [142]. CXCL10 is considered
the most crucial and potent chemokine in CXCR3-mediated
chemotaxis, as it is highly upregulated and its expression
robustly correlates with disease severity in inflammatory
disorders such as IBD, MS, and arthritis [143–145]. More-
over, the ability of CXCL10 to preferentially attract Th1
cells emphasizes its contribution to these diseases [146].
CXCL10 antagonism prevented or ameliorated inflammation
in numerous preclinical models of inflammatory disease
[142]. More specifically, neutralization of CXCL10 using
monoclonal antibody therapy proved eﬀective in various
experimental models of IBD [71–73]. In contrast, in a
more recent study, though antibody blockade of CXCL10
reduced intestinal epithelial cell proliferation and CXCR3+
cell migration in vitro and in vivo, it had no significant
eﬀect on disease in several preclinical models including IBD,
arthritis, and MS [147]. The reasons for the discrepancies
between these studies are unclear, but diﬀering methods
of antagonism and disease induction may play a part. For
instance, Byrne et al. used T-cell (CD4+CD45RBHi) transfer
to induce colitis, while earlier studies employed the IL-10KO
and DSS-induced colitis models. Future clinical trials are
likely to resolve these uncertainties (NCT01294410).
5.3. CXCR2. Since neutrophil influx into the intestinal
mucosa and resulting tissue damage is a major characteristic
of active IBD, especially UC, neutrophil-specific chemokine
receptors, and their ligands also represent potential ther-
apeutics. Neutrophils exclusively use integrins of the β2
family to arrest on the endothelium and antibodies against
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these integrins reduced tissue damage in experimental colitis
[148]. Engagement of the chemokines human IL-8/CXCL8
and the murine functional homologs CXCL1 and CXCL2
with their receptors CXCR1 and CXCR2 triggers numerous
signal transduction cascades, which in turn activate neu-
trophil recruitment to target tissues [149]. Inflammatory
mediators such as bacterial lipopolysaccharide (LPS), TNF-
α, and IL-1 stimulate the production of IL-8. Upregulation of
these chemokines in conjunction with polymorphonuclear
cells (PMN) infiltration into the inflamed intestinal mucosa
correlates well with the degree of active inflammation and
tissue injury in human and experimental models of IBD
[78, 150, 151]. CXCR2 is a well-established mediator of
PMN recruitment in preclinical models of inflammatory
disease [152–154]. A small molecule CXCR2 antagonist
(SB225002) was eﬀective in ameliorating trinitrobenzene
sulfonic acid- (TNBS-) induced colitis in mice, as was
an anti-CXCL1 antibody [155]. We used bioluminescence
imaging of adoptively transferred luciferase-expressing neu-
trophils to study the kinetics of neutrophil migration in
acute DSS-induced colitis. This enabled demonstration of
preferential recruitment of the neutrophils to the inflamed
colon and the blockade eﬀect of an anti-CXCL1 antibody on
the traﬃcking neutrophils [21].
5.4. The “Redundancy” Issue. The promise of drug inhibition
of chemokines and their receptors in IBD has not yet
been realized. The chemokine system is “redundant,” and
the same biological function can be carried out by several
chemokines and their receptors in vivo. This questions their
suitability as anti-inflammatory drug targets. However, it was
recently pointed out that the lack of progress in chemokine
strategies may not be due to “redundancy,” but rather to the
shortcomings in the approaches employed to target them
[156]. Clinical eﬃcacy of a small molecule CCR9 antagonist
was demonstrated in patients with moderate to severe CD
[157], proving that targeting one chemokine receptor can
be therapeutically successful in the treatment of chronic
inflammation.
6. Future Directions: MicroRNAs
Recent studies suggest that microRNAs (miRNAs) play
a specific role in the posttranscriptional regulation of
leukocyte traﬃcking. miRNAs are small (21−23 nucleotide)
noncoding RNAs that control gene expression. By targeting
complementary messenger RNAs (mRNAs) for degradation
or translational repression, they suppress the expression of
protein-coding genes. Blockade of miR-126 function using
an antagomir, a single-stranded antisense-likemolecule, sup-
pressed the Th2 response and subsequently the development
of disease in an experimental model of allergic asthma [158].
Interestingly, miR-126 was identified as one of a set of miR-
NAs expressed in endothelial cells [159, 160] and was shown
to inhibit TNF-induced endothelial expression of VCAM-1,
thus blocking leukocyte adhesion via its lymphocyte integrin
ligand α4β1 [161]. In terms of neutrophil traﬃcking, down-
regulation of E-selectin and ICAM-1 by miR-31 andmiR-17-
3, respectively, controlled neutrophil binding to endothelial
cells [162]. Inhibition of these miRNAs using specific
antagonists increased neutrophil adhesion to endothelial
cells in vitro, while transfecting with mimics (agonists) of
these miRNAs had the opposite eﬀect. This study suggests
that miRNAs negatively regulate inflammatory processes. In
another study, miR-7 downregulated expression of CD98, a
lymphocyte receptor that regulates integrin signaling [163].
CD98 levels were increased in the inflamed colons of patients
with CD, while miR-7 levels were decreased. Taken together,
the biological importance of miRNAs in the pathogenesis
of IBD is becoming clearer, and targeting miRNAs in the
context of leukocyte traﬃcking may be a safer approach for
future therapeutic opportunities.
7. Concluding Remarks
Targeting leukocyte migration is a realistic strategy, and
Natalizumab shows proof of principle. Compounds inhibit-
ing a single chemokine, such as CCR9, have also shown
promise, but awareness is necessary. Targeting molecules
such as miRNAs, histone deacetylases [164], or the fam-
ily of bromodomain proteins [165], which regulate gene
expression programs that govern endothelial cell function in
inflammatory settings, may represent a new generation of
drugs for IBD.
Abbreviations
BLI: Bioluminescent imaging
CD: Crohn’s disease
DC: Dendritic cell
DSS: Dextran sodium sulphate
GALT: Gut-associated lymphoid tissues
GPCRs: G-protein-coupled transmembrane
receptors
HEV: High endothelial venules
ICAM-1: Intercellular adhesion molecule 1
IBD: Inflammatory bowel disease
IL: Interleukin
KO: Knock out
LFA-1: Lymphocyte-function-associated antigen 1
LN: Lymph node
LPS: Lipopolysaccharide
MadCAM: Mucosal addressin-cell adhesion molecule 1
MLNs: Mesenteric lymph nodes
MPO: Myeloperoxidase
MRI: Magnetic resonance imaging
mRNA: Messenger RNA
miRNAs: MicroRNAs
MS: Multiple sclerosis
NK: Natural killer
PET: Positron emission tomography
PMN: Polymorphonuclear cells
PNAd: Peripheral lymph node addressin
PPs: Peyer’s patches
PSGL-1: P-selectin glycoprotein ligand 1
RA: Retinoic acid
RAR: Retinoic acid receptor
Clinical and Developmental Immunology 9
SPECT: Single photon emission computed tomography
S1P: Sphingosine-1-phosphate
TNF-α: Tumor necrosis factor-α
TNBS: Trinitrobenzene sulfonic acid
Tregs: T-regulatory cells
UC: Ulcerative colitis
V-CAM-1: Vascular-cell adhesion molecule 1.
Acknowledgments
The authors are supported, in part, by the Science Foun-
dation Ireland (SFI), the Higher Education Authority of
Ireland, the European Union, and GlaxoSmithKline Ltd
(GSK). The content of this paper was neither influenced nor
constrained by this fact.
References
[1] R. J. Xavier and D. K. Podolsky, “Unravelling the pathogene-
sis of inflammatory bowel disease,”Nature, vol. 448, no. 7152,
pp. 427–434, 2007.
[2] Y. Naito, T. Takagi, and T. Yoshikawa, “Molecular fingerprints
of neutrophil-dependent oxidative stress in inflammatory
bowel disease,” Journal of Gastroenterology, vol. 42, no. 10, pp.
787–798, 2007.
[3] W. Strober and I. J. Fuss, “Proinflammatory cytokines in the
pathogenesis of inflammatory bowel diseases,” Gastroenterol-
ogy, vol. 140, no. 6, pp. 1756–1767, 2011.
[4] S. Melgar and F. Shanahan, “Inflammatory bowel disease-
from mechanisms to treatment strategies,” Autoimmunity,
vol. 43, no. 7, pp. 463–477, 2010.
[5] J. H. Cho and S. R. Brant, “Recent insights into the genetics of
inflammatory bowel disease,” Gastroenterology, vol. 140, no.
6, pp. 1704–1712, 2011.
[6] S. R. Targan, “Current limitations of IBD treatment: where
do we go from here?” Annals of the New York Academy of
Sciences, vol. 1072, pp. 1–8, 2006.
[7] P. Rutgeerts, S. Vermeire, and G. Van Assche, “Biological
therapies for inflammatory bowel diseases,”Gastroenterology,
vol. 136, no. 4, pp. 1182–1197, 2009.
[8] M. J. Waldner and M. F. Neurath, “Novel cytokine-targeted
therapies and intestinal inflammation,” Current Opinion in
Pharmacology, vol. 9, no. 6, pp. 702–707, 2009.
[9] J. L. Gowans and E. J. Knight, “The route of re-circulation
of lymphocytes in the rat,” Proceedings of the Royal Society of
London Series B, vol. 159, pp. 257–282, 1964.
[10] R. J. Bennink, M. Peeters, P. Rutgeerts, and L. Mortelmans,
“Evaluation of early treatment response and predicting the
need for colectomy in active ulcerative colitis with 99mTc-
HMPAO white blood cell scintigraphy,” Journal of Nuclear
Medicine, vol. 45, no. 10, pp. 1698–1704, 2004.
[11] C. R. Parish, “Fluorescent dyes for lymphocyte migration and
proliferation studies,” Immunology and Cell Biology, vol. 77,
no. 6, pp. 499–508, 1999.
[12] C. M. Witt and K. Robbins, “Tracking thymocyte migration
in situ,” Seminars in Immunology, vol. 17, no. 6, pp. 421–430,
2005.
[13] M. J. Miller, S. H. Wei, M. D. Cahalan, and I. Parker,
“Autonomous T-cell traﬃcking examined in vivo with intrav-
ital two-photon microscopy,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 100,
no. 5, pp. 2604–2609, 2003.
[14] D. A. Mankoﬀ, “A definition of molecular imaging,” Journal
of Nuclear Medicine, vol. 48, no. 6, pp. 18–21, 2007.
[15] H. R. Herschman, “Micro-PET imaging and small animal
models of disease,” Current Opinion in Immunology, vol. 15,
no. 4, pp. 378–384, 2003.
[16] J. Nuyts, K. Vunckx, M. Defrise, and C. Vanhove, “Small
animal imaging with multi-pinhole SPECT,” Methods, vol.
48, no. 2, pp. 83–91, 2009.
[17] R. J. Bennink, J. Hamann, K. De Bruin, F. J. W. Ten Kate, S.
J. H. Van Deventer, and A. A. Te Velde, “Dedicated pinhole
SPECT of intestinal neutrophil recruitment in a mouse
model of dextran sulfate sodium-induced colitis,” Journal of
Nuclear Medicine, vol. 46, no. 3, pp. 526–531, 2005.
[18] M. F. Kircher, J. R. Allport, E. E. Graves et al., “In
vivo high resolution three-dimensional imaging of antigen-
specific cytotoxic T-lymphocyte traﬃcking to tumors,” Can-
cer Research, vol. 63, no. 20, pp. 6838–6846, 2003.
[19] O. R. Millington, B. H. Zinselmeyer, J. M. Brewer, P. Garside,
and C. M. Rush, “Lymphocyte tracking and interactions in
secondary lymphoid organs,” Inflammation Research, vol. 56,
no. 10, pp. 391–401, 2007.
[20] T. Troy, D. Jekic-McMullen, L. Sambucetti, and B. Rice,
“Quantitative comparison of the sensitivity of detection of
fluorescent and bioluminescent reporters in animal models,”
Molecular Imaging, vol. 3, no. 1, pp. 9–23, 2004.
[21] C. T. Murphy, G. Moloney, L. J. Hall et al., “Use of biolu-
minescence imaging to track neutrophil migration and its
inhibition in experimental colitis,” Clinical and Experimental
Immunology, vol. 162, no. 1, pp. 188–196, 2010.
[22] C. T. Murphy, G. Moloney, J. MacSharry et al., “Technical
Advance: function and eﬃcacy of an α4-integrin antagonist
using bioluminescence imaging to detect leukocyte traﬃck-
ing in murine experimental colitis,” Journal of Leukocyte
Biology, vol. 88, no. 6, pp. 1271–1278, 2010.
[23] R. T. Sadikot and T. S. Blackwell, “Bioluminescence imaging,”
Proceedings of the American Thoracic Society, vol. 2, no. 6, pp.
537–540, 2005.
[24] A. Y. Sheikh, S. A. Lin, F. Cao et al., “Molecular imaging of
bone marrow mononuclear cell homing and engraftment in
ischemic myocardium,” Stem Cells, vol. 25, no. 10, pp. 2677–
2684, 2007.
[25] G. L. Costa, M. R. Sandora, N. Nakajima et al., “Adopt-ive
immunotherapy of experimental autoimmune encephalo-
myelitis via T-cell delivery of the IL-12 p40 subunit,” Journal
of Immunology, vol. 167, no. 4, pp. 2379–2387, 2001.
[26] K. Ley, C. Laudanna, M. I. Cybulsky, and S. Nourshargh,
“Getting to the site of inflammation: the leukocyte adhesion
cascade updated,” Nature Reviews Immunology, vol. 7, no. 9,
pp. 678–689, 2007.
[27] K. Ley and G. S. Kansas, “Selectins in T-cell recruitment
to non-lymphoid tissues and sites of inflammation,” Nature
Reviews Immunology, vol. 4, no. 5, pp. 325–335, 2004.
[28] M. Sperandio, “Selectins and glycosyltransferases in leuko-
cyte rolling in vivo,” FEBS Journal, vol. 273, no. 19, pp. 4377–
4389, 2006.
[29] B. Rossi and G. Constantin, “Anti-selectin therapy for
the treatment of inflammatory diseases,” Inflammation and
Allergy Drug Targets, vol. 7, no. 2, pp. 85–93, 2008.
[30] S. Jalkanen, “Lymphocyte traﬃc to mucosa-associated lym-
phatic tissues,” Immunologic Research, vol. 10, no. 3-4, pp.
268–270, 1991.
10 Clinical and Developmental Immunology
[31] N. F. Pierce and W. C. Cray, “Determinants of the local-
ization, magnitude, and duration of a specific mucosal IgA
plasma cell response in enterically immunized rats,” Journal
of Immunology, vol. 128, no. 3, pp. 1311–1315, 1982.
[32] B. Xu, N. Wagner, L. N. Pham et al., “Lymphocyte homing
to bronchus-associated lymphoid tissue (BALT) is mediated
by L-selectin/PNAd, α4β1 integrin/VCAM-1, and LFA-1
adhesion pathways,” Journal of Experimental Medicine, vol.
197, no. 10, pp. 1255–1267, 2003.
[33] E. C. Butcher, M. Williams, K. Youngman, L. Rott, and M.
Briskin, “Lymphocyte traﬃcking and regional immunity,”
Advances in Immunology, no. 72, pp. 209–253, 1999.
[34] S. M. Kerfoot and P. Kubes, “Overlapping roles of P-selectin
and α4 integrin to recruit leukocytes to the central nervous
system in experimental autoimmune encephalomyelitis,”
Journal of Immunology, vol. 169, no. 2, pp. 1000–1006, 2002.
[35] N. Wagner, J. Lohler, E. J. Kunkel et al., “Critical role for β7
integrins in formation of the gut-associated lymphoid tissue,”
Nature, vol. 382, no. 6589, pp. 366–370, 1996.
[36] B. C. Chesnutt, D. F. Smith, N. A. Raﬄer, M. L. Smith,
E. J. White, and K. Ley, “Induction of LFA-1-dependent
neutrophil rolling on ICAM-1 by engagement of E-selectin,”
Microcirculation, vol. 13, no. 2, pp. 99–109, 2006.
[37] J. R. Mora, “Homing imprinting and immunomodulation in
the gut: role of dendritic cells and retinoids,” Inflammatory
Bowel Diseases, vol. 14, no. 2, pp. 275–289, 2008.
[38] I. Koboziev, F. Karlsson, and M. B. Grisham, “Gut-associated
lymphoid tissue, T-cell traﬃcking, and chronic intestinal
inflammation,” Annals of the New York Academy of Sciences,
vol. 1207, pp. E86–93, 2010.
[39] W. Strober, I. Fuss, and P. Mannon, “The fundamental
basis of inflammatory bowel disease,” Journal of Clinical
Investigation, vol. 117, no. 3, pp. 514–521, 2007.
[40] S. Kawachi, S. Jennings, J. Panes et al., “Cytokine and
endothelial cell adhesion molecule expression in interleukin-
10-deficient mice,” American Journal of Physiology, vol. 278,
no. 5, pp. G734–G743, 2000.
[41] J. Rivera-Nieves, T. Olson, G. Bamias et al., “L-selectin, α4β1,
and α 4β7 integrins participate in CD4+ T-cell recruitment to
chronically inflamed small intestine,” Journal of Immunology,
vol. 174, no. 4, pp. 2343–2352, 2005.
[42] H. S. Souza, C. C. S. Elia, J. Spencer, and T. T. MacDon-
ald, “Expression of lymphocyte-endothelial receptor-ligand
pairs, α4β7/MAdCAM-1 andOX40/OX40 ligand in the colon
and jejunum of patients with inflammatory bowel disease,”
Gut, vol. 45, no. 6, pp. 856–863, 1999.
[43] S. Arihiro, H. Ohtani, M. Suzuki et al., “Diﬀerential
expression of mucosal addressin cell adhesion molecule-
1 (MAdCAM-1) in ulcerative colitis and Crohn’s disease,”
Pathology International, vol. 52, no. 5-6, pp. 367–374, 2002.
[44] M. Briskin, D. Winsor-Hines, A. Shyjan et al., “Human
mucosal addressin cell adhesion molecule-1 is preferentially
expressed in intestinal tract and associated lymphoid tissue,”
American Journal of Pathology, vol. 151, no. 1, pp. 97–110,
1997.
[45] M. Abdelbaqi, J. H. Chidlow, K. M. Matthews et al.,
“Regulation of dextran sodium sulfate induced colitis by
leukocyte beta 2 integrins,” Laboratory Investigation, vol. 86,
no. 4, pp. 380–390, 2006.
[46] K. P. Pavlick, D. V. Ostanin, K. L. Furr et al., “Role of
T-cell-associated lymphocyte function-associated antigen-1
in the pathogenesis of experimental colitis,” International
Immunology, vol. 18, no. 2, pp. 389–398, 2006.
[47] J. Rivera-Nieves, G. Gorfu, and K. Ley, “Leukocyte adhesion
molecules in animal models of inflammatory bowel disease,”
Inflammatory Bowel Diseases, vol. 14, no. 12, pp. 1715–1735,
2008.
[48] D. L. Simmons, “Anti-adhesion therapies,” Current Opinion
in Pharmacology, vol. 5, no. 4, pp. 398–404, 2005.
[49] A. Goto, Y. Arimura, Y. Shinomura, K. Imai, and Y. Hinoda,
“Antisense therapy of MAdCAM-1 for trinitrobenzenesul-
fonic acid-induced murine colitis,” Inflammatory Bowel
Diseases, vol. 12, no. 8, pp. 758–765, 2006.
[50] M. Sans, J. Panes, E. Ardite et al., “VCAM-1 and ICAM-
1 mediate leukocyte-endothelial cell adhesion in rat experi-
mental colitis,” Gastroenterology, vol. 116, no. 4, pp. 874–883,
1999.
[51] J. K. MacDonald and J. W. McDonald, “Natalizumab
for induction of remission in Crohn’s disease,” Cochrane
Database of Systematic Reviews, no. 1, article CD006097,
2007.
[52] S. R. Targan, B. G. Feagan, R. N. Fedorak et al., “Natalizumab
for the treatment of active Crohn’s Disease: results of the
ENCORE Trial,” Gastroenterology, vol. 132, no. 5, pp. 1672–
1683, 2007.
[53] F. H. Gordon, M. I. Hamilton, S. Donoghue et al., “A
pilot study of treatment of active ulcerative colitis with
natalizumab, a humanized monoclonal antibody to alpha-4
integrin,”Alimentary Pharmacology and Therapeutics, vol. 16,
no. 4, pp. 699–705, 2002.
[54] S. Farkas,M.Hornung, C. Sattler et al., “BlockingMAdCAM-
1 in vivo reduces leukocyte extravasation and reverses
chronic inflammation in experimental colitis,” International
Journal of Colorectal Disease, vol. 21, no. 1, pp. 71–78, 2006.
[55] S. Kato, R. Hokari, K. Matsuzaki et al., “Amelioration
of murine experimental colitis by inhibition of mucosal
addressin cell adhesion molecule-1,” Journal of Pharmacology
and Experimental Therapeutics, vol. 295, no. 1, pp. 183–189,
2000.
[56] M. Takazoe, M. Watanabe, T. Kawaguchi et al., “S1066 Oral
Alpha-4 Integrin Inhibitor (AJM300) in patients with active
Crohn’s disease—a Randomized, Double-Blind, Placebo-
Controlled Trial,” Gastroenterology, vol. 136, p. A-181, 2009.
[57] D. Picarella, P. Hurlbut, J. Rottman, X. Shi, E. Butcher,
and D. J. Ringler, “Monoclonal antibodies specific for β7
integrin and mucosal addressin cell adhesion molecule-1
(MAdCAM-1) reduce inflammation in the colon of scidMice
reconstituted with CD45RBhigh CD4+ T cells,” Journal of
Immunology, vol. 158, no. 5, pp. 2099–2106, 1997.
[58] B. G. Feagan, G. R. Greenberg, G. Wild et al., “Treatment
of ulcerative colitis with a humanized antibody to the α4β7
integrin,” The New England Journal of Medicine, vol. 352, no.
24, pp. 2499–2507, 2005.
[59] B. W. Behm and S. J. Bickston, “Humanized antibody to the
alpha4beta7 integrin for induction of remission in ulcerative
colitis,” Cochrane Database of Systematic Reviews, no. 1,
article CD007571, 2009.
[60] B. G. Feagan, G. R. Greenberg, G. Wild et al., “Treatment
of active Crohn’s disease With MLN0002, a humanized
antibody to the α4β7 integrin,” Clinical Gastroenterology and
Hepatology, vol. 6, no. 12, pp. 1370–1377, 2008.
[61] K. Matsuzaki, Y. Tsuzuki, H. Matsunaga et al., “In vivo
demonstration of T lymphocyte migration and ameliora-
tion of ileitis in intestinal mucosa of SAMP1/Yit mice by
the inhibition of MAdCAM-1,” Clinical and Experimental
Immunology, vol. 140, no. 1, pp. 22–31, 2005.
Clinical and Developmental Immunology 11
[62] D. K. Podolsky, R. Lobb, N. King et al., “Attenuation of colitis
in the cotton-top tamarin by anti-α4 integrin monoclonal
antibody,” Journal of Clinical Investigation, vol. 92, no. 1, pp.
372–380, 1993.
[63] T. Taniguchi, H. Tsukada, H. Nakamura et al., “Eﬀects of
the anti-ICAM-1 monoclonal antibody on dextran sodium
sulphate-induced colitis in rats,” Journal of Gastroenterology
and Hepatology, vol. 13, no. 9, pp. 945–949, 1998.
[64] C. F. Bennett, D. Kornbrust, S. Henry et al., “An ICAM-1
antisense oligonucleotide prevents and reverses dextran sul-
fate sodium-induced colitis inmice,” Journal of Pharmacology
and Experimental Therapeutics, vol. 280, no. 2, pp. 988–1000,
1997.
[65] S. J. Van Deventer, M. K. Wedel, B. F. Baker, S. Xia, E.
Chuang, and P. B. Miner Jr., “A Phase II dose ranging,
double-blind, placebo-controlled study of alicaforsen enema
in subjects with acute exacerbation of mild to moderate
left-sided ulcerative colitis,” Alimentary Pharmacology and
Therapeutics, vol. 23, no. 10, pp. 1415–1425, 2006.
[66] S. J. H. Van Deventer, J. A. Tami, and M. K. Wedel, “A
randomised, controlled, double blind, escalating dose study
of alicaforsen enema in active ulcerative colitis,” Gut, vol. 53,
no. 11, pp. 1646–1651, 2004.
[67] R. C. Burns, J. Rivera-Nieves, C. A. Moskaluk, S. Matsumoto,
F. Cominelli, and K. Ley, “Antibody blockade of ICAM-
1 and VCAM-1 ameliorates inflammation in the SAMP-
1/Yit adoptive transfer model of Crohn’s disease in mice,”
Gastroenterology, vol. 121, no. 6, pp. 1428–1436, 2001.
[68] J. Rivera-Nieves, J. Ho, G. Bamias et al., “Antibody Blockade
of CCL25/CCR9 Ameliorates Early but not Late Chronic
Murine Ileitis,” Gastroenterology, vol. 131, no. 5, pp. 1518–
1529, 2006.
[69] M. J. Walters, Y. Wang, N. Lai et al., “Characterization
of CCX282-B, an orally bioavailable antagonist of the
CCR9 chemokine receptor, for treatment of inflammatory
bowel disease,” Journal of Pharmacology and Experimental
Therapeutics, vol. 335, no. 1, pp. 61–69, 2010.
[70] B. Eksteen and D. H. Adams, “GSK-1605786, a selective
small-molecule antagonist of the CCR9 chemokine receptor
for the treatment of Crohn’s disease,” IDrugs, vol. 13, no. 7,
pp. 472–481, 2010.
[71] J. G. Hyun, G. Lee, J. B. Brown et al., “Anti-interferon-
inducible chemokine, CXCL10, reduces colitis by impairing
T helper-1 induction and recruitment inmice,” Inflammatory
Bowel Diseases, vol. 11, no. 9, pp. 799–805, 2005.
[72] U. P. Singh, S. Singh, D. D. Taub, and J.W. Lillard, “Inhibition
of IFN-γ-inducible protein-10 abrogates colitis in IL-10-/-
mice,” Journal of Immunology, vol. 171, no. 3, pp. 1401–1406,
2003.
[73] S. Sasaki, H. Yoneyama, K. Suzuki et al., “Blockade of CXCL
10 protects mice from acute colitis and enhances crypt cell
survival,” European Journal of Immunology, vol. 32, no. 11,
pp. 3197–3205, 2002.
[74] W. Zhong, J. K. Kolls, H. Chen, F. McAllister, P. D. Oliver, and
Z. Zhang, “Chemokines orchestrate leukocyte traﬃcking in
inflammatory bowel disease,” Frontiers in Bioscience, vol. 13,
no. 5, pp. 1654–1664, 2008.
[75] R. Fo¨rster, A. Schubel, D. Breitfeld et al., “CCR7 coordinates
the primary immune response by establishing functional
microenvironments in secondary lymphoid organs,” Cell,
vol. 99, no. 1, pp. 23–33, 1999.
[76] S. K. Bromley, S. Y. Thomas, and A. D. Luster, “Chemokine
receptor CCR7 guides T-cell exit from peripheral tissues and
entry into aﬀerent lymphatics,” Nature Immunology, vol. 6,
no. 9, pp. 895–901, 2005.
[77] A. Viola and A. D. Luster, “Chemokines and their receptors:
drug targets in immunity and inflammation,” Annual Review
of Pharmacology and Toxicology, vol. 48, pp. 171–197, 2008.
[78] C. Banks, A. Bateman, R. Payne, P. Johnson, and N.
Sheron, “Chemokine expression in IBD. Mucosal chemokine
expression is unselectively increased in both ulcerative colitis
and Crohn’s disease,” Journal of Pathology, vol. 199, no. 1, pp.
28–35, 2003.
[79] J. Puleston, M. Cooper, S. Murch et al., “A distinct subset of
chemokines dominates the mucosal chemokine response in
inflammatory bowel disease,” Alimentary Pharmacology and
Therapeutics, vol. 21, no. 2, pp. 109–120, 2005.
[80] D. Kawashima, N. Oshitani, Y. Jinno et al., “Augmented
expression of secondary lymphoid tissue chemokine and
EBI1 ligand chemokine in Crohn’s disease,” Journal of Clinical
Pathology, vol. 58, no. 10, pp. 1057–1063, 2005.
[81] J. R. Mora, M. R. Bono, N. Manjunath et al., “Selective
imprinting of gut-homing T cells by Peyer’s patch dendritic
cells,” Nature, vol. 424, no. 6944, pp. 88–93, 2003.
[82] A. J. Stagg, M. A. Kamm, and S. C. Knight, “Intestinal
dendritic cells increase T-cell expression of α4β7 integrin,”
European Journal of Immunology, vol. 32, no. 5, pp. 1445–
1454, 2002.
[83] B. Johansson-Lindbom, M. Svensson, M. A. Wurbel, B.
Malissen, G. Ma´rquez, andW. Agace, “Selective generation of
gut tropic T cells in gut-associated lymphoid tissue (GALT):
requirement for GALT dendritic cells and adjuvant,” Journal
of Experimental Medicine, vol. 198, no. 6, pp. 963–969, 2003.
[84] J. R. Mora, G. Cheng, D. Picarella, M. Briskin, N. Buchanan,
and U. H. Von Andrian, “Reciprocal and dynamic control
of CD8 T-cell homing by dendritic cells from skin- and
gut-associated lymphoid tissues,” Journal of Experimental
Medicine, vol. 201, no. 2, pp. 303–316, 2005.
[85] B. Johansson-Lindbom, M. Svensson, O. Pabst et al., “Func-
tional specialization of gut CD103+ dendritic cells in the
regulation of tissue-selective T-cell homing,” Journal of
Experimental Medicine, vol. 202, no. 8, pp. 1063–1073, 2005.
[86] E. Jaensson, H. Uronen-Hansson, O. Pabst et al., “Small
intestinal CD103+ dendritic cells display unique functional
properties that are conserved between mice and humans,”
Journal of Experimental Medicine, vol. 205, no. 9, pp. 2139–
2149, 2008.
[87] M. Iwata, A. Hirakiyama, Y. Eshima, H. Kagechika, C.
Kato, and S. Y. Song, “Retinoic acid imprints gut-homing
specificity on T cells,” Immunity, vol. 21, no. 4, pp. 527–538,
2004.
[88] S. Manicassamy and B. Pulendran, “Retinoic acid-dependent
regulation of immune responses by dendritic cells and
macrophages,” Seminars in Immunology, vol. 21, no. 1, pp.
22–27, 2009.
[89] M. Svensson, B. Johansson-Lindbom, F. Zapata et al.,
“Retinoic acid receptor signaling levels and antigen dose
regulate gut homing receptor expression on CD8+ T cells,”
Mucosal Immunology, vol. 1, no. 1, pp. 38–48, 2008.
[90] A. J. Stagg, K. E. Norin, T. Midtvedt, M. A. Kamm, S. C.
Knight, and B. Bjo¨rkste´n, “Mesenteric dendritic cells from
germ-free mice cause less T-cell stimulation but still induce
α4β7 integrin,” Microbial Ecology in Health and Disease, vol.
19, no. 3, pp. 171–183, 2007.
[91] S. C. Ng, M. A. Kamm, A. J. Stagg, and S. C. Knight,
“Intestinal dendritic cells: their role in bacterial recognition,
12 Clinical and Developmental Immunology
lymphocyte homing, and intestinal inflammation,” Inflam-
matory Bowel Diseases, vol. 16, no. 10, pp. 1787–1807, 2010.
[92] J. L. Coombes, K. R. R. Siddiqui, C. V. Arancibia-Ca´rcamo
et al., “A functionally specialized population of mucosal
CD103+ DCs induces Foxp3+ regulatory T cells via a
TGF-β -and retinoic acid-dependent mechanism,” Journal of
Experimental Medicine, vol. 204, no. 8, pp. 1757–1764, 2007.
[93] S. G. Kang, C. Wang, S. Matsumoto, and C. H. Kim, “High
and low vitamin A therapies induce distinct foxP3+ T-
cell subsets and eﬀectively control intestinal inflammation,”
Gastroenterology, vol. 137, no. 4, pp. 1391–e6, 2009.
[94] H. Chi, “Sphingosine-1-phosphate and immune regulation:
traﬃcking and beyond,” Trends in Pharmacological Sciences,
vol. 32, no. 1, pp. 16–24, 2011.
[95] D. Meyer zu Heringdorf and K. H. Jakobs, “Lysophos-
pholipid receptors: signalling, pharmacology and regulation
by lysophospholipid metabolism,” Biochimica et Biophysica
Acta, vol. 1768, no. 4, pp. 923–940, 2007.
[96] S. S. Chae, R. L. Proia, and T. Hla, “Constitutive expression of
the S1P1 receptor in adult tissues,” Prostaglandins and Other
Lipid Mediators, vol. 73, no. 1-2, pp. 141–150, 2004.
[97] M. Graeler and E. J. Goetzl, “Activation-regulated expression
and chemotactic function of sphingosine 1-phosphate recep-
tors in mouse splenic T cells,” FASEB Journal, vol. 16, no. 14,
pp. 1874–1878, 2002.
[98] C. Jaillard, S. Harrison, B. Stankoﬀ et al., “Edg8/S1P5: an
oligodendroglial receptor with dual function on process
retraction and cell survival,” Journal of Neuroscience, vol. 25,
no. 6, pp. 1459–1469, 2005.
[99] M. Matloubian, C. G. Lo, G. Cinamon et al., “Lymphocyte
egress from thymus and peripheral lymphoid organs is
dependent on S1P receptor 1,” Nature, vol. 427, no. 6972, pp.
355–360, 2004.
[100] L. R. Shiow, D. B. Rosen, N. Brdicˇkova´ et al., “CD69
acts downstream of interferon-α/β to inhibit S1P 1 and
lymphocyte egress from lymphoid organs,” Nature, vol. 440,
no. 7083, pp. 540–544, 2006.
[101] T. H. M. Pham, T. Okada, M. Matloubian, C. G. Lo, and
J. G. Cyster, “S1P1 receptor signaling overrides retention
mediated by Gαi-coupled receptors to promote T-cell egress,”
Immunity, vol. 28, no. 1, pp. 122–133, 2008.
[102] A. Rathinasamy, N. Czeloth, O. Pabst, R. Fo¨rster, and G.
Bernhardt, “The origin and maturity of dendritic cells
determine the pattern of sphingosine 1-phosphate receptors
expressed and required for eﬃcient migration,” Journal of
Immunology, vol. 185, no. 7, pp. 4072–4081, 2010.
[103] M. L. Allende, M. Bektas, B. G. Lee et al., “Sphingosine-
1-phosphate lyase deficiency produces a pro-inflammatory
response while impairing neutrophil traﬃcking,” Journal of
Biological Chemistry, vol. 286, no. 9, pp. 7348–7358, 2011.
[104] T. Walzer, L. Chiossone, J. Chaix et al., “Natural killer
cell traﬃcking in vivo requires a dedicated sphingosine 1-
phosphate receptor,” Nature Immunology, vol. 8, no. 12, pp.
1337–1344, 2007.
[105] S. Spiege and S. Milstien, “The outs and the ins of
sphingosine-1-phosphate in immunity,” Nature Reviews
Immunology, vol. 11, pp. 403–415, 2011.
[106] A. J. Ammit, A. T. Hastie, L. C. Edsall et al., “Sphingosine
1-phosphate modulates human airway smooth muscle cell
functions that promote inflammation and airway remodeling
in asthma,” The FASEB Journal, vol. 15, no. 7, pp. 1212–1214,
2001.
[107] M. Kitano, T. Hla, M. Sekiguchi et al., “Sphingosine 1-
phosphate/sphingosine 1-phosphate receptor 1 signaling in
rheumatoid synovium: regulation of synovial proliferation
and inflammatory gene expression,” Arthritis and Rheuma-
tism, vol. 54, no. 3, pp. 742–753, 2006.
[108] V. Brinkmann, A. Billich, T. Baumruker et al., “Fingolimod
(FTY720): discovery and development of an oral drug to treat
multiple sclerosis,”Nature Reviews Drug Discovery, vol. 9, no.
11, pp. 883–897, 2010.
[109] K. Chiba, “A new therapeutic approach for autoimmune
diseases by the sphingosine 1-phosphate receptor modulator,
fingolimod (FTY720),” Yakugaku Zasshi, vol. 129, no. 6, pp.
655–665, 2009.
[110] Y. Y. Lan, A. De Creus, B. L. Colvin et al., “The sphingosine-1-
phosphate receptor agonist FTY720 modulates dendritic cell
traﬃcking in vivo,” American Journal of Transplantation, vol.
5, no. 11, pp. 2649–2659, 2005.
[111] K. Budde, R. L. Schmouder, B. Nashan et al., “Pharmaco-
dynamics of single doses of the novel immunosuppressant
FTY720 in stable renal transplant patients,” American Journal
of Transplantation, vol. 3, no. 7, pp. 846–854, 2003.
[112] K. Budde, R. L. Schmouder, R. Brunkhorst et al., “First
human trial of FTY720, a novel immunomodulator, in stable
renal transplant patients,” Journal of the American Society of
Nephrology, vol. 13, no. 4, pp. 1073–1083, 2002.
[113] B. D. Kahan, J. L. Karlix, R. M. Ferguson et al., “Phar-
macodynamics, pharmacokinetics, and safety of multiple
doses of FTY720 in stable renal transplant patients: a
multicenter, randomized, placebo-controlled, phase I study,”
Transplantation, vol. 76, no. 7, pp. 1079–1084, 2003.
[114] H. Tedesco-Silva, G. Mourad, B. D. Kahan et al., “FTY720,
a novel immunomodulator: eﬃcacy and safety results from
the first phase 2A study in de novo renal transplantation,”
Transplantation, vol. 79, no. 11, pp. 1553–1560, 2005.
[115] C. Daniel, N. Sartory, N. Zahn, G. Geisslinger, H. H.
Radeke, and J. M. Stein, “FTY720 ameliorates Th1-mediated
colitis in mice by directly aﬀecting the functional activity of
CD4+CD25+ regulatory T cells,” Journal of Immunology, vol.
178, no. 4, pp. 2458–2468, 2007.
[116] Y. Deguchi, A. Andoh, Y. Yagi et al., “The S1P receptor mod-
ulator FTY720 prevents the development of experimental
colitis in mice,” Oncology Reports, vol. 16, no. 4, pp. 699–703,
2006.
[117] C. Daniel, N. A. Sartory, N. Zahn et al., “FTY720 ameliorates
oxazolone colitis in mice by directly aﬀecting T helper type 2
functions,” Molecular Immunology, vol. 44, no. 13, pp. 3305–
3316, 2007.
[118] R. Fujii, T. Kanai, Y. Nemoto et al., “FTY720 suppresses
CD4+CD44highCD62L- eﬀector memory T-cell-mediated
colitis,” American Journal of Physiology, vol. 291, no. 2, pp.
G267–G274, 2006.
[119] T. Mizushima, T. Ito, D. Kishi et al., “Therapeutic eﬀects of
a new lymphocyte homing reagent FTY720 in interleukin-
10 gene-deficient mice with colitis,” Inflammatory Bowel
Diseases, vol. 10, no. 3, pp. 182–192, 2004.
[120] A. S. Awad, H. Ye, L. Huang et al., “Selective sphingo-
sine 1-phosphate 1 receptor activation reduces ischemia-
reperfusion injury in mouse kidney,” American Journal of
Physiology, vol. 290, no. 6, pp. F1516–F1524, 2006.
[121] D. T. Bolick, S. Srinivasan, K. W. Kim et al., “Sphingosine-
1-phosphate prevents tumor necrosis factor-α-mediated
monocyte adhesion to aortic endothelium in mice,” Arte-
riosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 5,
pp. 976–981, 2005.
[122] J. Song, C. Matsuda, Y. Kai et al., “A novel sphingosine
1-phosphate receptor agonist, 2-amino-2-propanediol
Clinical and Developmental Immunology 13
hydrochloride (KRP-203), regulates chronic colitis in
interleukin-10 gene-deficient mice,” Journal of Pharmacology
and Experimental Therapeutics, vol. 324, no. 1, pp. 276–283,
2008.
[123] D. H.Miller, O. A. Khan,W. A. Sheremata et al., “A controlled
trial of natalizumab for relapsingmultiple sclerosis,” The New
England Journal of Medicine, vol. 348, no. 1, pp. 15–23, 2003.
[124] R. A. Rudick, W. H. Stuart, P. A. Calabresi et al., “Natal-
izumab plus interferon beta-1a for relapsing multiple scle-
rosis,” The New England Journal of Medicine, vol. 354, no. 9,
pp. 911–923, 2006.
[125] O. Stuve, R. Gold, A. Chan, E. Mix, U. Zettl, and B.
C. Kieseier, “α4-Integrin antagonism with natalizumab :
eﬀects and adverse eﬀects,” Journal of Neurology, vol. 255,
supplement 6, pp. 58–65, 2008.
[126] P. E. Hesterberg, D. Winsor-Hines, M. J. Briskin et al., “Rapid
resolution of chronic colitis in the cotton-top tamarin with
an antibody to a gut-homing integrin α4β7,” Gastroenterol-
ogy, vol. 111, no. 5, pp. 1373–1380, 1996.
[127] C. F. Barish, “Alicaforsen therapy in inflammatory bowel
disease,” Expert Opinion on Biological Therapy, vol. 5, no. 10,
pp. 1387–1391, 2005.
[128] B. Yacyshyn,W. Y. Chey,M. K.Wedel, R. Z. Yu, D. Paul, and E.
Chuang, “A randomized, double-masked, placebo-controlled
study of alicaforsen, an antisense inhibitor of intercellular
adhesionmolecule 1, for the treatment of subjects with active
Crohn’s disease,” Clinical Gastroenterology and Hepatology,
vol. 5, no. 2, pp. 215–220, 2007.
[129] B. R. Yacyshyn, W. Y. Chey, J. Goﬀ et al., “Double blind,
placebo controlled trial of the remission inducing and steroid
sparing properties of an ICAM-1 antisense oligodeoxynu-
cleotide, alicaforsen (ISIS 2302), in active steroid dependent
Crohn’s disease,” Gut, vol. 51, no. 1, pp. 30–36, 2002.
[130] S. Schreiber, S. Nikolaus, H. Malchow et al., “Absence of
eﬃcacy of subcutaneous antisense ICAM-1 treatment of
chronic active Crohn’s disease,” Gastroenterology, vol. 120,
no. 6, pp. 1339–1346, 2001.
[131] P. Miner Jr., M. Wedel, B. Bane, and J. Bradley, “An
enema formulation of alicaforsen, an antisense inhibitor
of intercellular adhesion molecule-1, in the treatment of
chronic, unremitting pouchitis,” Alimentary Pharmacology
and Therapeutics, vol. 19, no. 3, pp. 281–286, 2004.
[132] S. Bommakanti, A. Patil, C. Eshoa, and C. R. Chitambar,
“Case reports: efalizumab-associated lymphoproliferative
disease,” Journal of Drugs in Dermatology, vol. 6, no. 6, pp.
646–648, 2007.
[133] H. Okigami, K. Takeshita, M. Tajimi et al., “Inhibition of
eosinophilia in vivo by a small molecule inhibitor of very
late antigen (VLA)-4,” European Journal of Pharmacology, vol.
559, no. 2-3, pp. 202–209, 2007.
[134] J. Cortijo, M. J. Sanz, A. Iranzo et al., “A small molecule,
orally active, α4β1/ α4β7 dual antagonist reduces leukocyte
infiltration and airway hyper-responsiveness in an experi-
mental model of allergic asthma in Brown Norway rats,”
British Journal of Pharmacology, vol. 147, no. 6, pp. 661–670,
2006.
[135] B. Johansson-Lindbom andW.W. Agace, “Generation of gut-
homing T cells and their localization to the small intestinal
mucosa,” Immunological Reviews, vol. 215, no. 1, pp. 226–
242, 2007.
[136] C. Koenecke and R. Fo¨rster, “CCR9 and inflammatory bowel
disease,” Expert Opinion on Therapeutic Targets, vol. 13, no.
3, pp. 297–306, 2009.
[137] J. D.Wermers, E. N.McNamee,M. A.Wurbel, P. Jedlicka, and
J. Rivera-Nieves, “The Chemokine receptor CCR9 is required
for the T-cell-mediated regulation of chronic ileitis in mice,”
Gastroenterology, vol. 140, no. 5, pp. 1526–1535.e3, 2011.
[138] M. A. Wurbel, M. G. McIntire, P. Dwyer, and E. Fiebiger,
“CCL25/CCR9 interactions regulate large intestinal inflam-
mation in a murine model of acute colitis,” PLoS ONE, vol. 6,
no. 1, article e16442, 2011.
[139] E. J. Kunkel, J. J. Campbell, G. Haraldsen et al., “Lymphocyte
CC chemokine receptor 9 and epithelial thymus-expressed
chemokine (TECK) expression distinguish the small intesti-
nal immune compartment: epithelial expression of tissue-
specific chemokines as an organizing principle in regional
immunity,” Journal of Experimental Medicine, vol. 192, no. 5,
pp. 761–767, 2000.
[140] L. Piali, C. Weber, G. LaRosa et al., “The chemokine recep-
tor CXCR3 mediates rapid and shear-resistant adhesion-
induction of eﬀector T lymphocytes by the chemokines IP10
and Mig,” European Journal of Immunology, vol. 28, no. 3, pp.
961–972, 1998.
[141] R. Bonecchi, G. Bianchi, P. P. Bordignon et al., “Diﬀerential
expression of chemokine receptors and chemotactic respon-
siveness of type 1 T helper cells (Th1s) and Th2s,” Journal of
Experimental Medicine, vol. 187, no. 1, pp. 129–134, 1998.
[142] U. P. Singh, C. Venkataraman, R. Singh, and J. W. Lillard
Jr., “CXCR3 axis: role in inflammatory bowel disease and its
therapeutic implication,” Endocrine, Metabolic and Immune
Disorders Drug Targets, vol. 7, no. 2, pp. 111–123, 2007.
[143] E. Scarpini, D. Galimberti, P. Baron et al., “IP-10 and MCP-
1 levels in CSF and serum from multiple sclerosis patients
with diﬀerent clinical subtypes of the disease,” Journal of the
Neurological Sciences, vol. 195, no. 1, pp. 41–46, 2002.
[144] R. Hanaoka, T. Kasama, M. Muramatsu et al., “A novel
mechanism for the regulation of IFN-gamma inducible
protein-10 expression in rheumatoid arthritis,” Arthritis
Research and Therapy, vol. 5, no. 2, pp. R74–81, 2003.
[145] A. Aggarwal, S. Agarwal, and R. Misra, “Chemokine and
chemokine receptor analysis reveals elevated interferon-
inducible protein-10 (IP)-10/CXCL10 levels and increased
number of CCR5+ and CXCR3+CD4 T cells in synovial fluid
of patients with enthesitis-related arthritis (ERA),” Clinical
and Experimental Immunology, vol. 148, no. 3, pp. 515–519,
2007.
[146] P. Loetscher, A. Pellegrino, J. H. Gong et al., “The Ligands
of CXC Chemokine Receptor 3, I-TAC, Mig, and IP10,
Are Natural Antagonists for CCR3,” Journal of Biological
Chemistry, vol. 276, no. 5, pp. 2986–2991, 2001.
[147] F. R. Byrne, A. Winters, D. Brankow et al., “An antibody to
IP-10 is a potent antagonist of cell migration in vitro and in
vivo and does not aﬀect disease in several animal models of
inflammation,” Autoimmunity, vol. 42, no. 3, pp. 171–182,
2009.
[148] M. J. H. J. Palmen, C. D. Dijkstra, M. B. Van Der Ende, A.
S. Pena, and E. P. Van Rees, “Anti-CD11b/CD18 antibodies
reduce inflammation in acute colitis in rats,” Clinical and
Experimental Immunology, vol. 101, no. 2, pp. 351–356, 1995.
[149] Y. Kobayashi, “Neutrophil infiltration and chemokines,”
Critical Reviews in Immunology, vol. 26, no. 4, pp. 307–315,
2006.
[150] S. Melgar, M. Drmotova, E. Rehnstro¨m, L. Jansson, and
E. Michae¨lsson, “Local production of chemokines and
prostaglandin E2 in the acute, chronic and recovery phase of
murine experimental colitis,” Cytokine, vol. 35, no. 5-6, pp.
275–283, 2006.
14 Clinical and Developmental Immunology
[151] H. Hanai, K. Takeuchi, T. Iida et al., “Relationship between
fecal calprotectin, intestinal inflammation, and peripheral
blood neutrophils in patients with active ulcerative colitis,”
Digestive Diseases and Sciences, vol. 49, no. 9, pp. 1438–1443,
2004.
[152] P. L. Podolin, B. J. Bolognese, J. J. Foley et al., “A potent
and selective nonpeptide antagonist of CXCR2 inhibits acute
and chronic models of arthritis in the rabbit,” Journal of
Immunology, vol. 169, no. 11, pp. 6435–6444, 2002.
[153] J. M. Schuh, K. Blease, and C. M. Hogaboam, “CXCR2 is
necessary for the development and persistence of chronic
fungal asthma in mice,” Journal of Immunology, vol. 168, no.
3, pp. 1447–1456, 2002.
[154] P. Buanne, E. Di Carlo, L. Caputi et al., “Crucial pathophys-
iological role of CXCR2 in experimental ulcerative colitis in
mice,” Journal of Leukocyte Biology, vol. 82, no. 5, pp. 1239–
1246, 2007.
[155] A. F. Bento, D. F. P. Leite, R. F. Claudino, D. B. Hara, P. C.
Leal, and J. B. Calixto, “The selective nonpeptide CXCR2
antagonist SB225002 ameliorates acute experimental colitis
inmice,” Journal of Leukocyte Biology, vol. 84, no. 4, pp. 1213–
1221, 2008.
[156] T. J. Schall and A. E. Proudfoot, “Overcoming hurdles in
developing successful drugs targeting chemokine receptors,”
Nature Reviews Immunology, vol. 11, no. 5, pp. 355–363,
2011.
[157] S. Keshav, D. Johnson, P. Bekker, and T. J. Schall, “PROTECT-
1 study demonstrated eﬃcacy of the intestine-specific
chemokine receptor antagonist CCX282-B (Traficet-EN)
in treatment of patients with moderate-to-severe Crohn’s
disease,” Gastroenterology, vol. 136, p. A-65, 2009.
[158] J. Mattes, A. Collison, M. Plank, S. Phipps, and P. S. Foster,
“Antagonism of microRNA-126 suppresses the eﬀector func-
tion of T H2 cells and the development of allergic airways
disease,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 106, no. 44, pp. 18704–18709,
2009.
[159] Y. Sua´rez, C. Ferna´ndez-Hernando, J. S. Pober, and W. C.
Sessa, “Dicer dependent microRNAs regulate gene expres-
sion and functions in human endothelial cells,” Circulation
Research, vol. 100, no. 8, pp. 1164–1173, 2007.
[160] L. Poliseno, A. Tuccoli, L. Mariani et al., “MicroRNAs
modulate the angiogenic properties of HUVECs,” Blood, vol.
108, no. 9, pp. 3068–3071, 2006.
[161] T. A. Harris, M. Yamakuchi, M. Ferlito, J. T. Mendell,
and C. J. Lowenstein, “MicroRNA-126 regulates endothelial
expression of vascular cell adhesion molecule 1,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 105, no. 5, pp. 1516–1521, 2008.
[162] Y. Sua´rez, C. Wang, T. D. Manes, and J. S. Pober, “Cut-
ting edge: TNF-induced microRNAs regulate TNF-induced
expression of E-selectin and intercellular adhesion molecule-
1 on human endothelial cells: feedback control of inflamma-
tion,” Journal of Immunology, vol. 184, no. 1, pp. 21–25, 2010.
[163] H. T. T. Nguyen, G. Dalmasso, Y. Yan et al., “MicroRNA-7
modulates CD98 expression during intestinal epithelial cell
diﬀerentiation,” Journal of Biological Chemistry, vol. 285, no.
2, pp. 1479–1489, 2010.
[164] R. Glauben and B. Siegmund, “Inhibition of histone deacety-
lases in inflammatory bowel diseases,” Molecular Medicine,
vol. 17, no. 5-6, pp. 426–433, 2011.
[165] E. Nicodeme, K. L. Jeﬀrey, U. Schaefer et al., “Suppression of
inflammation by a synthetic histonemimic,”Nature, vol. 468,
no. 7327, pp. 1119–1123, 2010.
